Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation

American Journal of the Medical Sciences

Volumn 314, Issue 5, 1997, Pages 292-298

  Agaliotis, Dimitrios P ^a   Ballester, Oscar F ^a,b   Mattox, Todd ^a   Hiemenz, John W ^a   Fields, Karen K ^a   Zorsky, Paul E ^a   Goldstein, Steven C ^a   Perkins, Janelle B ^a   Rosen, Raquel M ^a   Elfenbein, Gerald J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Complications; High dose chemotherapy; Ifosfamide; Nephrotoxicity; Stem cell transplantation

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BICARBONATE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DATA ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MORBIDITY; NEPHROTOXICITY; POTASSIUM BLOOD LEVEL; RETROSPECTIVE STUDY; SOLID TUMOR; STEM CELL TRANSPLANTATION; TREATMENT PLANNING;

EID: 0030838328     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199711000-00004     Document Type: Article

References (25)

1. Willemse PHB, de Jong PE, Elema JD, Mulder NH. Severe renal failure following high-dose ifosfamide and mensa. Cancer Chemother Pharmacol. 1989;23:329-30.
2. Skinner R, Sharkey I M, Pearson ADJ, Craft AW. Ifosfamide, mensa, and nephrotoxicity in children. J Clin Oncol. 1993;11:173-190.
3. Brock N, Pohl J, Stekar J. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention-I: Experimental studies on the urotoxicity of alkylating compounds. Eur J Cancer. 1981;17:595-607.
4. Beckwith C, Flaharty KK, Cheung AK, Beatty PG. Fanconi's syndrome due to ifosfamide. Bone Marrow Transplant. 1993;11:71-3.
5. Lewis LD, Burton LC, Harper PG, Rogers HJ. Uroepithelial and nephrotubular toxicity in patients receiving ifosfamide/mensa: Measurement of urinary N-acetyl-G-D- glucosaminidase and G-2-microglobulin. Eur J Cancer. 1992; 28A(12):1976-81.
6. Norpoth K. Studies on the metabolism of ifosfamide (NSC-109724) in man. Cancer Treat Rep. 1976;60:437-43.
7. Goldin A. Ifosfamide in experimental tumor systems. Semin Oncol. 1982;9(suppl 1):14-23.
8. Berger DP, Fiebig HH, Winterhalter BR, Wallbrecher E, Henss H. Preclinical phase II study of ifosfamide in human tumor xenografts in vivo. Cancer Chemother Pharmacol. 1990;26(suppl):S7-11.
9. Hilgard P, Herdrich K, Brade W: Ifosfamide-Current aspects and perspectives. Cancer Treat Rev. 1983; 10(suppl A):183-92.
10. Shaw PJ, Eden OB. Ifosfamide in pediatric oncology: Tried but not tested? Lancet. 1990;1:1022-3.
11. Davies SM, Pearson ADJ, Craft AW. Toxicity of high-dose ifosfamide in children. Cancer Chemother Pharmacol. 1989;24(suppl):S8-10.
12. Shore R, Greenberg M, Geary D, Koren G. Ifosfamide-induced nephrotoxicity in children. Pediatr Nephrol. 1992; 6:162-5.
13. Skinner R, Pearson ADJ, Price L, Coulthard MG, Craft AW. Nephrotoxicity after ifosfamide. Arch Dis Child. 1990;65:732-8.
14. Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: An international society of pediatric oncology report. J Clin Oncol. 1991;9,12:2177-82.
15. Tournade MF, Lemerle J, Brunat-Mentigny, Bachelot C, Roche H, Taboureau O, et al. Ifosfamide is an active drug in Wilm's tumor: A phase II study conducted by the French society of pediatric oncology. J Clin Oncol. 1988;6(5):793-6.
16. Pratt CB, Meyer WH, Jenkins JJ, Avery L, McKay CP, Wyatt RJ, et al. Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol. 1991;9(8):1495-9.
17. Caron HN, Abeling N, van Gennip A, de Kraker J, Voute PA. Hyper aminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and palatinate containing regimens. Med Pediatr Oncol. 1992;20:42-7.
18. Devalck C, Ismaili K, Ferster A, Sariban E. Acute ifosfamide-induced proximal tubular toxic reaction. J Pediatr (letter). 1991;118(2):325-6.
19. Rossi R, Helmchen TJ, Shellong G. Tubular function and histological findings in ifosfamide-induced renal Fanconi syndrome - a report of two cases. Eur J Pediatr. 1992;151:384-7.
20. Heney D, Wheeldon J, Rushworth P, Chapman C, Lewis IJ, Bailey CC. Progressive renal toxicity due to ifosfamide. Arch Dis Child. 1991;66:966-70.
21. Goren MP, Wright RK, Horowitz ME, Pratt CB. Ifosfamide-induced subclinical tubular nephrotoxicity despite mensa. Cancer Treat Rep. 1987;71(2):127-30.
22. Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M et al. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol. 1992;10:1712-22.
23. Fields KK, Zorsky PE, Hiemenz JW, Kronish LE, Elfenbein GJ. Ifosfamide, carboplatin, and etoposide: A new regimen with a broad spectrum of activity. J Clin Oncol. 1994;12(3):544-52.
24. Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, et al. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: Toxicity profile. J Clin Oncol. 1994;13:323-32.
25. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant. 1995;15:373-9.